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Purpose: To clarify the association of cluster of differentiation 36 (CD36) variants with polypoidal choroidal vasculopathy
(PCV) and compare them with those in typical neovascular age-related macular degeneration (tAMD).
Methods: We included 349 Japanese AMD patients (210 PCV, 139 tAMD) and 198 age-matched controls. Four tag single-
nucleotide polymorphisms (SNPs)—rs10499862, rs3173798, rs3211883, and rs3173800—in the CD36 region were
genotyped using the TaqMan assay. Allelic and genotypic frequencies of the SNPs were tested.
Results: Although none of the SNPs tested were associated with PCV, the allelic frequencies of rs3173798 and rs3173800
were significantly different between PCV and tAMD patients. Genotype association analysis demonstrated different
associations of these two SNPs between PCV and tAMD in the genotype model. Haplotype analysis revealed that the
association of the major haplotype (T-T-T-T) at four selected SNPs in CD36 differed significantly between PCV and
tAMD patients.
Conclusions: The CD36 region may be associated with the difference in genetic susceptibility for PCV and tAMD.
Age-related macular degeneration (AMD) is a leading
cause of central vision loss in the elderly in industrialized
countries [1]. Although the number of patients with AMD has
increased remarkably over the years, the pathology of AMD
is  not  well  understood  [2].  Advanced  AMD  is  clinically
classified  into  atrophic  AMD  and  exudative  AMD.  In
exudative  AMD,  there  are  two  characteristic  phenotypes
distinct from typical neovascular AMD (tAMD), which are
called polypoidal choroidal vasculopathy (PCV) [3,4] and
retinal angiomatous proliferation [5]. These two phenotypes
are  known  to  have  different  aspects  from  tAMD  in  their
natural courses, as well as different responses to interventions
such  as  photodynamic  therapy  (PDT)  and  anti–vascular
endothelial growth factor therapy, although the reasons for
this  remain  unknown  [6-10].  Recently,  several  genetic
association  studies  have  been  conducted  to  explain  the
different characteristics among the phenotypes of exudative
AMD and their susceptibility to several interventions, mainly
PDT [11-19].
Cluster of differentiation 36 (CD36) is a multifunctional
molecule that plays an important role in lipid metabolism,
angiogenesis,  inflammation,  and  scavenging  oxidative
stresses  [20-22],  all  of  which  may  be  involved  in  the
pathogenesis of AMD and in the mechanism whereby PDT
functions.  We  previously  demonstrated  the  association  of
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coding variants in the CD36 region with the incidence of
neovascular AMD (corresponding to tAMD in the present
report) in the Japanese population [23]. In that study, two
variants  of  single  nucleotide  polymorphisms  (SNPs)—
rs3173798 and rs3211883 on introns 3 and 4, which have high
linkage disequilibrium—showed the greatest association with
susceptibility to neovascular AMD. However, it has not been
determined  whether  this  association  is  general  to  all
exudative AMD or  specific  for  tAMD.    We  hypothesized
that the genetic variants in CD36 may be differently associated
with genetic susceptibilities to tAMD and PCV. Since PCV is
known to have a better response to PDT than tAMD [7,8], we
considered that the scavenging ability of CD36 for reactive
oxygen species generated by PDT might be different between
tAMD and PCV, which could influence the effect of PDT.
We previously reported that coding variants of the elastin
gene (ELN) were associated with PCV but not with tAMD
[13]. However, two recent reports with larger cohorts showed
the opposite results: The ELN polymorphism was associated
with  tAMD  but  not  with  PCV  [24,25].  Although  the
association of elastin gene variants with tAMD and PCV is
still inconclusive, these results might have been generated due
to statistical type 1 and type 2 errors. In the present study, we
included  a  sufficient  number  of  subjects  based  on  power
analysis to prevent these errors.
In this study, we genotyped four tag SNPs located on
introns 3 and 4 of the CD36 gene, and analyzed the association
between these variants and the incidence of PCV, as well as
tAMD, in a Japanese population.
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Study participants: This is an extension study of a previous
report  [23].  The  study  was  approved  by  the  Institutional
Review Board of the Kobe University Graduate School of
Medicine,  and  was  conducted  in  accordance  with  the
Declaration  of  Helsinki.  Written  informed  consent  was
obtained  from  all  subjects.  All  cases  in  this  study  were
Japanese  individuals  recruited  from  the  Department  of
Ophthalmology at Kobe University Hospital in Japan.
The study included 349 Japanese AMD patients (210
PCV,  139  tAMD)  and  198  age-matched  controls  who
accepted  DNA  sampling.  The  tAMD  group  in  this  study
included the patients of our previous study, along with 30 new
patients. The control group in this study included the subjects
of  the  previous  study  and  16  more  individuals  [23].  All
patients received ophthalmic examinations, including visual
acuity  measurements  with  refractive  correction,  slit-lamp
biomicroscopy of the fundi, color fundus photographs, optical
coherence  tomography,  fluorescein  angiography,  and
indocyanine green angiography (ICGA). All PCV subjects
enrolled in this study met the criteria of definite cases of PCV
as  proposed  by  the  Japanese  Study  Group  of  Polypoidal
Choroidal  Vasculopathy  [26].  ICGA  showed  a  choroidal
origin of the polypoidal lesions in all PCV cases, typically
with vascular networks in the posterior poles and subretinal
reddish-orange protrusions corresponding to the polypoidal
lesions on ICGA. In contrast, all tAMD patients had clear
images  of  choroidal  neovascular  networks  on  ICGA.  The
classification of the AMD phenotype was performed by three
independent retinal specialists for each case under masked
conditions  for  the  genotype.  Only  those  cases  whose
diagnoses were matched by all three readers were included in
this study. The details of the participants are listed in Table 1.
Single-nucleotide polymorphism selection: The four tag SNPs
—rs10499862,  rs3173798,  rs3211883,  and  rs3173800  on
introns 3 and 4 in the CD36 region—were selected based on
our  previous  study  [23],  including  SNPs  which  were
significantly associated with tAMD (allelic nominal p-values
<0.01). These four SNPs were in a single haplotype block
using  the  algorithm  based  on  the  solid  spine  of  linkage
disequilibrium.
Genotyping:  Genomic  DNA  was  extracted  from  the
peripheral blood using the QIAamp DNA Blood Maxi Kit
(Qiagen, Valencia, CA). Genotyping was performed using
TaqMan® SNP Genotyping Assays or Custom TaqMan® SNP
Genotyping Assays (Applied Biosystems, Foster City, CA) on
a  StepOnePlus™  Real-Time  PCR  System  (Applied
Biosystems)  in  accordance  with  the  supplier’s
recommendations.
Statistical  analysis:  All  SNPs  were  evaluated  for  Hardy–
Weinberg  equilibrium  using  the  χ2  test  (one  degree  of
freedom)  with  SNPAlyze  version  7.0.1  (DYNACOM,
Yokohama,  Japan).  The  allelic  and  genotype  frequency
distributions were compared among tAMD, PCV, and control
subjects using a χ2 test with one or two degrees of freedom for
the allelic and genotypic tests, respectively. To avoid false-
positive results, the Bonferroni or permutation correction was
added for each comparison. P values <0.05 were considered
to be statistically significant.
To exclude a potential stratification, our study cohort was
examined by Structure 2.0 [27] using 26 unlinked genome-
wide SNPs, as shown in our previous report [23].
RESULTS
None of the SNPs reported in the present study showed any
significant deviations from the Hardy–Weinberg equilibrium
over  the  entire  sample  (p>0.05).  Table  2  summarizes  the
minor allelic frequencies for all SNPs and the results from a
single-SNP  association  study.  Significant  differences  in
minor  allelic  frequencies  were  found  in  all  SNPs  tested
between the tAMD and control subjects, as shown in our
previous report [23], but there was no difference in minor
allelic frequencies between the PCV and control subjects.
Meanwhile, significant differences were found between PCV
and  tAMD  patients  at  rs3173798  and  rs3173800.  The
statistical  powers  of  single-SNP  association  analysis  at
rs3173798  and  rs3173800  were  about  0.94  and  0.92,
respectively (alpha error <0.05), in the comparison between
PCV and tAMD. The genotype association analysis revealed
significant  associations  of  rs3173798  and  rs3211883  with
tAMD, but not with PCV in the dominant model (Table 3). In
addition, the most significant differences were found between
PCV and tAMD patients at rs3173798 and rs3173800 in the
TABLE 1. DATA SUMMARY OF PCV AND TAMD PATIENTS AND CONTROL SUBJECTS.
Factors PCV tAMD Control
Number of subjects 210 139 198
Gender (male/female) 166/44 108/31 119/79
Mean age±SD (years) 73.8±7.5 75.3±7.3 72.1±5.9
Median age (years) 75 76 72
Age range (years) 51–93 55–94 56–95
          PCV: polypoidal choroidal vasculopathy, tAMD: typical neovascular AMD.
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122genotype (additive) model. In the haplotype analysis, the most
frequent  haplotype  (T-T-T-T)  at  rs10499862,  rs3173798,
rs3211883,  and  rs3173800  showed  the  most  significant
difference in association between PCV and tAMD (Table 4).
There was no evidence of significant stratification in our study
cohort (Pr [K=1 >0.99]).
DISCUSSION
We genotyped four tag SNPs in the CD36 region, and found
that the minor allelic frequencies at SNPs rs3173798 and
rs3173800 and the haplotype at four selected SNPs in the
CD36 region were significantly associated with the difference
in genetic susceptibility to PCV and tAMD. Namely, T, T
alleles were less frequent than C, A alleles in PCV than in
tAMD patients at rs3173798 and rs3173800, respectively.
Moreover, the T-T-T-T haplotype at rs10499862, rs3173798,
rs3211883, and rs3173800 on introns 3 and 4 in the CD36
region was significantly less frequent in PCV than in tAMD.
Although  our  previous  report  demonstrated  an
association of SNPs in the CD36 region with neovascular
AMD [23], the phenotype specificity of these SNPs remained
to  be  elucidated.  The  present  study  suggests  a  different
association of CD36 in genetic susceptibility for PCV and
tAMD,  which  may  contribute  to  the  different  clinical
characteristics of PCV (i.e., natural course and the response
to PDT or ranibizumab) from tAMD [3,4,6-9]. Since the SNPs
at rs10499862,rs3173798,rs3211883, and rs3173800 were not
covered by the gene chips used in previous genome-wide
association studies [28,29], they could not be detected as
possible  causative  SNPs  for  AMD  in  those  studies.  The
present study, as well as our previous report [23], further
suggested an association of this region in CD36 with the
incidence of tAMD. However, these SNPs did not remain
significant in the prevalence of PCV. Moreover, a statistically
significant difference was detected in the association of this
region between tAMD and PCV. This suggests a different
association  of  the  CD36  region  with  the  phenotype  of
neovascular AMD, although the details have not yet been
clarified.  A  recent  in  vivo  study  demonstrated  that  a
downregulation of CD36 in capillary sprout endothelial cells
facilitated angiogenesis [30]. Rats carrying a specific genetic
variant of CD36 have been found to be more susceptible to
light-induced retinal damage, and are more likely to develop
age-related  retinal  degeneration  and  choriocapillary
rarefaction [31]. CD36 is involved in diverse physiologic and
pathological  processes,  including  scavenger  receptor
functions,  transforming  growth  factor-β  activation,  lipid
metabolism, angiogenesis, atherogenesis, and inflammation,
depending  on  the  ligands  with  which  CD36  can  interact
[20-22]. In particular, the scavenging ability of CD36 for
oxidative stress is critical to manage AMD, since oxidative
stress is widely recognized as an important component in the
pathogenesis of AMD [32,33] and in the mechanism whereby
PDT works to occlude neovascular tracts [34]. A recent in
vitro study reported that the uptake of oxidized low-density
lipoprotein (oxLDL) induces the expression of several genes
related to oxidative stress, inflammation, and apoptosis in
retinal  pigment  epithelium  cells  [35].  An
immunohistochemical study reported the presence of oxLDL
in  surgically  excised  choroidal  neovascularization
membranes [36]. Moreover, the verteporfin used in PDT binds
with  serum  LDL,  and  this  complex  is  incorporated  into
choroidal neovascularization tissues [37]. Although it is not
known whether lipid metabolism and oxidative stress play
different roles in the pathogenesis between tAMD and PCV,
the present study implied different genetic susceptibilities for
each  AMD  phenotype.  Interestingly,  recent  reports
demonstrated a difference between tAMD and PCV in their
histological  findings  and  systemic  risk  factors  [38,39].
Moreover,  our  previous  study  demonstrated  a  different
association of an elastin gene polymorphism with tAMD and
PCV [13].
The biologic basis of the association with the haplotype
in CD36 is currently unknown, because the haplotype in the
present  study  does  not  reside  in  the  coding  sequence  of
CD36. FASTSNP [40] gave the information that rs3173798
is located at splicing site with medium-high effect, but it was
not shown whether it is located at splice donor site or acceptor
TABLE 2. SUMMARY OF SINGLE-SNP ASSOCIATION ANALYSIS ON GENE CD36.
      Minor allele frequency Allelic nominal p-value (Bonferroni p-value)
SNP ID Location Major/
Minor
PCV tAMD Control PCV versus
control
tAMD versus control PCV versus tAMD
rs10499862 Intron 3 T/C 0.14 0.11 0.18 0.058 (0.23) 0.0066 (0.026) 0.28 (1.0)
rs3173798 Intron 3 T/C 0.46 0.33 0.44 0.57 (1.0) 0.005 (0.020) 0.00081 (0.0032)
rs3211883 Intron 4 T/A 0.35 0.28 0.4 0.19 (0.76) 0.0017 (0.0068) 0.043 (0.17)
rs3173800 Intron 4 A/T 0.26 0.38 0.28 0.41 (1.0) 0.0071 (0.028) 0.0005 (0.0020)
          SNP: single nucleotide polymorphism, PCV: polypoidal choroidal vasculopathy, tAMD: typical neovascular AMD.
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124site [41]. Thus, the SNPs in this region could have noncoding
effects  on  gene  expression  and  function.  A  recent  study
demonstrated that the C allele at rs3173798 tended to increase
CD36  expression  while  reducing  high-density  lipoprotein
levels  [41,42].  Since  the  C  allele  at  rs3173798  was  less
frequent in the tAMD group than the PCV and control groups,
the reduced expression of CD36 might be correlated with
tAMD but not PCV pathogenesis. Moreover, Picard et al. have
recently demonstrated an accumulation of oxLDL in Bruch’s
membrane  among  aged  CD36  knockout  mice  [43].  The
oxLDL accelerates an accumulation of deposits in Bruch’s
membrane and causes drusen. Interestingly, drusens are more
frequently seen in tAMD than PCV [44]. However, exhaustive
resequencing  of  this  locus  may  elucidate  potentially
undiscovered  and  more  important  causative  variants.  In
addition, it is essential to perform replication studies using
other  cohorts  to  verify  and  conclude  the  associations  of
CD36 variants with tAMD and PCV.
The limitation of this study was a possible influence of
lipid metabolism on AMD pathogenesis [45,46]. Since CD36
is  known  to  associate  with  the  metabolic  syndrome  and
hyperlipidemia  [41,47],  CD36  variants  may  indirectly
contribute to AMD via abnormal lipid metabolism. However,
the  results  of  this  study  suggest  a  possible  role  of  lipid
metabolism in the different pathogeneses between PCV and
tAMD.
In conclusion, the present study suggested some clinical
possibilities for genetic association analysis that can be further
investigated to determine the specific pathogenesis of PCV as
distinct from that of tAMD.
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